Sleep Study (Polysomnography) — What to Expect, Costs & Results — Cost, Top Hospitals & Success Rates | MyMedicPlus

A sleep study, or polysomnography (PSG), is a comprehensive overnight diagnostic test performed in a specialized sleep laboratory to record and analyze multiple physiological parameters simultaneously during natural sleep, enabling definitive diagnosis of a wide spectrum of sleep disorders. In-laboratory PSG is the gold standard, recording up to 20 simultaneous data channels throughout a 7–9 hour overnight recording. Electroencephalography (EEG — typically 6 channels: F3, F4, C3, C4, O1, O2 referenced to mastoids) records brain electrical activity, enabling trained technologists and computer algorithms to stage sleep into wakefulness, NREM stage N1 (light sleep), N2 (true sleep onset), N3 (slow-wave or deep sleep), and REM sleep. Electro-oculography (EOG — bilateral) records eye movements to distinguish REM from NREM sleep. Surface electromyography (EMG) at the chin (submentalis) and bilateral anterior tibialis muscles detects muscle atonia during REM (important for REM sleep behavior disorder) and periodic limb movements. Continuous pulse oximetry measures arterial oxygen saturation (SpO2) and heart rate. Nasal pressure transducer and oral-nasal thermistor measure airflow, detecting apneas (complete cessation ≥10 seconds) and hypopneas (partial flow reduction with arousal or desaturation). Thoracic and abdominal inductance plethysmography belts record respiratory effort to differentiate obstructive from central events. Body position sensor identifies positional OSA. Video monitoring captures parasomnia behaviors. Raw data is manually scored by a board-certified sleep technologist (RPSGT) or physician per AASM scoring rules. Home sleep apnea testing (HSAT) using portable 3–4 channel monitors recording airflow, respiratory effort, pulse oximetry, and heart rate is an appropriate and cost-effective alternative for uncomplicated suspected OSA in adults without significant cardiorespiratory comorbidity, reducing costs by 50–75% versus lab PSG.

Sleep studies diagnose and characterize a comprehensive range of sleep disorders that cannot be reliably identified from clinical history alone. Obstructive sleep apnea (OSA) is the most common indication — PSG quantifies severity via the apnea-hypopnea index (AHI) and provides essential data for CPAP titration (a separate titration PSG or split-night PSG may be performed). Central sleep apnea, characterized by apneas without respiratory effort (Cheyne-Stokes respiration in heart failure, opioid-induced central apnea), requires PSG with respiratory effort belts to distinguish from OSA and guide treatment with adaptive servo-ventilation. REM sleep behavior disorder (RBD), where the normal REM muscle atonia is absent causing patients to physically act out dreams — a major injury risk and prodromal marker for synucleinopathy — requires video-PSG with dedicated chin and limb EMG to document REM without atonia. Narcolepsy diagnosis mandates both an overnight PSG (to confirm adequate nocturnal sleep and rule out other causes of EDS) followed immediately by a Multiple Sleep Latency Test (MSLT) measuring daytime sleep propensity across five scheduled nap opportunities. Periodic limb movement disorder (PLMD), defined as ≥15 periodic limb movements per hour of sleep in adults causing arousals, is diagnosed by limb EMG scoring during PSG. Sleep-related hypoventilation syndromes (obesity hypoventilation, neuromuscular disease) require PSG with CO2 monitoring (transcutaneous or end-tidal). Parasomnias including sleepwalking, sleep terrors, and other complex behaviors require video-PSG to characterize the sleep stage of origin and document the behavior objectively. Sleep-related seizures are differentiated from parasomnias by EEG channels during PSG.

In-laboratory PSG is indicated for patients with high clinical suspicion for sleep disorders that cannot be adequately evaluated by simpler methods. The AASM recommends PSG when: HSAT is negative but clinical suspicion for OSA remains high (OSA must be confirmed before starting CPAP therapy), the patient has significant cardiopulmonary disease, hypoventilation syndrome, neuromuscular disease, or central sleep apnea where HSAT is insufficient; for CPAP pressure titration (attended titration PSG); when REM sleep behavior disorder, narcolepsy, PLMD, or parasomnia evaluation is required; or when atypical presentations or pediatric cases need comprehensive evaluation. HSAT (portable home sleep apnea test) is appropriate for uncomplicated adults with high pre-test probability of moderate-to-severe OSA, without suspicion of other sleep disorders, without significant comorbidities (heart failure, COPD, neuromuscular disease), and without hypersomnia requiring narcolepsy evaluation. Pre-study preparation: patients should avoid caffeine (coffee, tea, energy drinks) for 24 hours, alcohol for 48 hours, and sedating medications (antihistamines, benzodiazepines) unless medically essential and discussed with the ordering physician, as these alter sleep architecture and scoring. Patients should maintain their usual sleep schedule for the week prior to avoid sleep deprivation or excessive sleep — both alter MSLT results. Hair products (gels, oils, sprays) should be washed out before arrival as they impede electrode attachment. Patients are encouraged to bring their usual pillow, comfortable sleep attire, and any prescribed medications.

Sleep diagnostics range from comprehensive laboratory-based studies to portable home devices, selected based on clinical indication:

• Attended in-laboratory polysomnography (PSG): The gold standard diagnostic study. Performed in a dedicated sleep laboratory with monitoring of EEG (brain activity — sleep staging), EOG (eye movements — REM detection), EMG (chin and leg muscle activity), ECG, pulse oximetry, nasal/oral airflow, chest and abdominal respiratory effort, snoring microphone, and video recording. Provides comprehensive simultaneous data across all sleep stages. Required for complex cases: suspected central sleep apnea, narcolepsy (with MSLT same day), parasomnias (video recording essential), nocturnal seizures, and patients with significant cardiorespiratory comorbidity where HSAT may not be safe or sufficient.
• Split-night PSG: The first portion of the night establishes the diagnostic PSG; if AHI exceeds threshold (typically ≥40 events/hour in the first 2 hours), the second portion is used for CPAP titration in the same night. Saves a separate titration night and reduces cost.
• CPAP/PAP titration PSG: Attended study specifically to calibrate optimal CPAP/BiPAP/ASV pressure for diagnosed OSA. Increasingly replaced by APAP auto-titration at home.
• Home sleep apnea test (HSAT): Type III portable monitoring (no EEG) measures airflow, respiratory effort, oximetry, heart rate, and position. Appropriate for uncomplicated suspected obstructive sleep apnea in adults without significant comorbidity. Underestimates AHI by 15–20% vs. PSG (sleep time is actual clock time not confirmed sleep time). Increasingly the first-line diagnostic in primary care-initiated OSA pathways given cost and accessibility advantages.
• Multiple Sleep Latency Test (MSLT): Performed the morning after a diagnostic PSG. Five 20-minute nap opportunities every 2 hours — mean sleep onset latency ≤8 minutes with ≥2 sleep-onset REM periods (SOREMPs) confirms narcolepsy. Essential for narcolepsy diagnosis; also evaluates idiopathic hypersomnia.
• Maintenance of Wakefulness Test (MWT): Objective assessment of ability to remain awake during 40-minute sessions in a darkened room — used for occupational driving fitness assessment and treatment response evaluation in narcolepsy patients.
• Actigraphy: Wrist-worn accelerometry over 1–2 weeks estimates sleep-wake patterns from movement data. Useful for circadian rhythm disorders, hypersomnia, and insomnia monitoring. Less accurate than PSG for sleep staging but valuable for longitudinal tracking and circadian assessment.

Polysomnography remains the gold standard for sleep disorder diagnosis, providing objective, quantified data that enables precise diagnosis, treatment selection, and therapy monitoring. For OSA, in-laboratory PSG has sensitivity exceeding 95% and specificity exceeding 90% for detecting moderate-to-severe OSA (AHI ≥15) and simultaneously stages all sleep, measures oxygen desaturation severity (nadir SpO2, cumulative time below 90%), and detects comorbid conditions. CPAP titration PSG identifies the optimal therapeutic pressure individualized to the patient, avoiding both under-treatment (persistent events) and over-treatment (high pressure causing central apneas or arousal). MSLT for narcolepsy diagnosis achieves sensitivity of approximately 78% and specificity of 93% when interpreted with clinical context and prior PSG data. Video-PSG for REM sleep behavior disorder provides the definitive diagnosis, characterizing behavior severity and injury risk, and allows initiation of neuroprotective monitoring — RBD is now recognized as a prodromal marker for synucleinopathies (Parkinson's disease, DLB, MSA) in 80% of patients within 15 years, making early diagnosis clinically important. HSAT reduces patient burden, improves access in geographic areas without sleep laboratories, and costs 50–75% less than in-laboratory PSG while demonstrating equivalent diagnostic accuracy (sensitivity 79–94% for AHI ≥15) in appropriate low-complexity patients per the ApneaLink, AASM Level III device validation studies. Split-night PSG (first half diagnostic, second half titration in the same night if AHI exceeds 40) reduces cost and inconvenience in clear-cut severe OSA presentations.

Sleep studies are among the safest diagnostic procedures in medicine, carrying no radiation exposure, no intravenous access requirements (unless CO2 monitoring via arterial line is needed), and no anesthesia risks. The primary practical risks are methodological rather than physical. The first-night effect — a well-documented phenomenon where sleep in an unfamiliar laboratory environment is lighter, more fragmented, and contains less slow-wave and REM sleep than habitual home sleep — can affect diagnostic sensitivity, particularly for parasomnias that occur predominantly in slow-wave sleep. Mild scalp irritation from electrode conductive gel is the most common physical complaint, resolving with washing. For HSAT specifically, technical failure (loose sensors, memory malfunction, insufficient battery) occurs in 10–15% of recordings, necessitating repeat testing or laboratory PSG — increasing the overall cost and delaying diagnosis. HSAT does not record EEG, so sleep staging is impossible; AHI is calculated as an respiratory event index (REI) divided by total recording time (not total sleep time), which systematically underestimates true AHI by 10–30% compared to PSG and may miss clinically significant OSA in patients with low sleep efficiency. HSAT cannot diagnose narcolepsy, PLMD, parasomnias, or sleep-related seizures. Scoring variability between sleep technologists and laboratories is a recognized limitation — inter-rater agreement for hypopnea scoring averages 70–80%, highlighting the importance of using AASM-accredited laboratories with standardized scoring practices. Patients with obesity, COPD, or central hypoventilation may have inadequate monitoring without CO2 data on standard HSAT.

The results and follow-up pathway after a sleep study are structured around the specific findings:

• Results timeline: In-laboratory PSG results are typically available within 5–10 business days after manual sleep staging and report generation by a sleep physician. HSAT results from automated analysis are often available same day or within 24–48 hours; physician interpretation adds 1–5 days.
• OSA diagnosis and CPAP initiation: Patients with confirmed OSA are fitted for CPAP, instructed on mask selection, and commenced on auto-titrating CPAP (APAP) or prescribed fixed pressure from titration study. Clinical review at 1 month to assess adherence, residual AHI from device data, and symptom improvement.
• Narcolepsy diagnosis: MSLT confirming narcolepsy leads to specialist sleep medicine referral, pharmacotherapy initiation (modafinil first-line), and occupational counselling regarding driving restrictions.
• Negative study: A negative sleep study in a patient with high clinical suspicion warrants either repeat testing (HSAT has 20% false-negative rate in mild OSA — laboratory PSG indicated) or exploration of alternative diagnoses (circadian rhythm disorders, insufficient sleep syndrome, periodic limb movement disorder).
• Periodic limb movement disorder (PLMD): Found on leg EMG channels — PLM index ≥15/hour with associated arousals diagnoses PLMD. Treated with alpha-2-delta agents (gabapentin, pregabalin) or dopamine agonists; RLS workup initiated concurrently.

Sleep study costs vary dramatically by geography, laboratory type, and study complexity. In India, in-laboratory overnight diagnostic PSG costs $200–600 USD at private sleep centers in major metropolitan areas (Mumbai, Delhi, Bangalore, Chennai, Hyderabad); HSAT costs $100–300 USD. CPAP titration PSG adds $200–500 USD. The two-day MSLT protocol (PSG night plus MSLT day) costs $400–800 USD at specialized sleep laboratories. Split-night PSG (diagnostic + titration combined) costs $300–600 USD. In Thailand, a popular medical tourism destination for sleep diagnostics, PSG costs $400–800 USD at leading hospitals such as Bumrungrad and Bangkok Hospital. Singapore offers high-quality sleep laboratories (Raffles Hospital, National University Hospital) with PSG costs of $800–1,500 USD. In the United States, in-laboratory PSG costs $1,500–3,500 USD (facility fees plus interpretation) without insurance; with Medicare coverage, patient responsibility is typically 20% after Part B deductible. HSAT costs $300–600 USD, with insurance typically covering for suspected OSA. MSLT in the USA costs $2,500–5,000 USD. In the United Kingdom, NHS referral to a sleep center provides PSG without direct cost to the patient on referral; private PSG costs £600–1,500. In Australia, private PSG costs AUD $1,000–2,500, with Medicare rebates available for in-laboratory studies. Germany, France, and major European centers offer PSG through national health insurance systems with minimal patient co-payment.

In appropriate clinical contexts, simpler diagnostic approaches may be used before or instead of full PSG:

• Home sleep apnea test (HSAT): For uncomplicated suspected OSA in adults without significant comorbidity — validated alternative to attended PSG with equivalent clinical outcomes in appropriate patients (AASM and ATS guidelines). Significantly lower cost and no waiting list for laboratory. Not appropriate for suspected central sleep apnea, narcolepsy, complex parasomnias, or patients with significant cardiac or respiratory disease.
• Overnight pulse oximetry: A simple screening test — oximetry desaturation index (ODI) ≥15 events/hour has 90% specificity for moderate-to-severe OSA. Inexpensive and widely available. A positive oximetry result can initiate empirical CPAP treatment in low-risk patients; a negative result does not exclude OSA and requires PSG for definitive evaluation.
• Clinical prediction tools: STOP-BANG questionnaire (8 items), Berlin questionnaire, and Epworth Sleepiness Scale stratify OSA risk to guide referral prioritization. STOP-BANG ≥5 has 83% sensitivity for moderate-to-severe OSA. These tools guide referral decisions but do not replace diagnostic testing.
• Actigraphy for circadian disorders: For suspected delayed or advanced sleep phase disorder, non-24-hour sleep-wake disorder, and irregular sleep-wake rhythm, 2-week actigraphy recording (combined with sleep diary) is the recommended diagnostic approach per AASM guidelines — PSG is not needed for circadian diagnosis.